Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus DERMOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus DERMOTIC.
DERMA-SMOOTHE/FS vs DERMOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid